Experimental treatment could be 'game-changing' for genetic ALS, experts say

An experimental treatment for the rapidly progressive disease ALS, or amyotrophic lateral sclerosis, has been called potentially "game-changing."

The treatment, called tofersen, was found to slow the decline of muscular function associated with a genetic form of ALS in a study presented at the annual meeting of the American Academy of Neurology.

Tofersen is still in its developmental stages, and how much it could cost is not yet known.

NS faculty member Dr. Jonathan Glass, professor and director of the Emory ALS Center at the Emory University School of Medicine, was mentioned in this story.

Click here to view the full story in CNN Health.